{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling within the tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units)",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit",
          "line_ref": "L39"
        }
      ],
      "caveat": "The interferon response magnitude may vary across different tumor types and model systems, as some mechanistic readouts were strongest in specific settings rather than uniformly across all tested conditions."
    },
    {
      "claim_id": "C02",
      "claim": "Interferon-associated antigen processing and presentation pathways increase following mRNA vaccination, leading to broader MHC-I peptide presentation.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome",
          "line_ref": "L29"
        },
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome",
          "line_ref": "L28"
        }
      ],
      "caveat": "While the expansion of the MHC-I peptidome was substantial, the clinical significance of this expansion for T-cell recognition depends on the specific peptide repertoire and T-cell avidity distributions."
    },
    {
      "claim_id": "C03",
      "claim": "PD-L1 pathway activity increases following mRNA vaccination, creating a rationale for combining with checkpoint blockade.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue",
          "line_ref": "L32"
        }
      ],
      "caveat": "The causal relationship between mRNA vaccination and PD-L1 upregulation requires further mechanistic validation, as observed changes could reflect indirect inflammatory effects rather than direct transcriptional regulation."
    },
    {
      "claim_id": "C04",
      "claim": "Combined intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in preclinical mouse models.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change",
          "line_ref": "L33"
        },
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control",
          "line_ref": "L36"
        }
      ],
      "caveat": "Preclinical efficacy in mouse models may not translate directly to human tumors due to differences in tumor immunobiology, T-cell receptor repertoires, and the tumor microenvironment."
    },
    {
      "claim_id": "C05",
      "claim": "Retrospective clinical data suggests that patients with prior SARS-CoV-2 mRNA vaccination demonstrate improved survival outcomes when receiving ICI treatment.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; vaccination timing varied across patients, and residual confounding from tumor type heterogeneity and treatment history likely influences the observed survival benefit."
    }
  ]
}